Erythropoiesis lagging? pIgA1 steps in to assist Epo.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 22064409.
- Also identified by DOI 10.1038/nm.2501 and PMC identifier 3339494.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although erythropoietin (Epo) is commonly used as a therapy for anemia, recent studies have suggested that Epo therapy is associated with adverse outcomes. A new study shows that polymeric IgA1 positively regulates erythropoiesis through binding to transferrin receptor 1 (Tfr1), suggesting new therapeutic routes for anemia (pages 1456–1465).
Medical subject headings
- Anemia
- Cell Proliferation
- Erythroblasts
- Erythropoiesis
- Immunoglobulin A